Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Manish B Jhawar & Greg Flaker. (2012) Preventing stroke in atrial fibrillation patients – clinical utility of oral anticoagulants. Journal of Blood Medicine 3, pages 1-13.
Read now
Read now
Keren Borensztajn & C Arnold Spek. (2011) Blood coagulation factor Xa as an emerging drug target. Expert Opinion on Therapeutic Targets 15:3, pages 341-349.
Read now
Read now
Jennifer Carreiro & Jack Ansell. (2008) Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict. Expert Opinion on Investigational Drugs 17:12, pages 1937-1945.
Read now
Read now
Articles from other publishers (41)
Xu Bingzheng, Ren Jingnan, Bao Ligang & Chen Jianping. (2021) The effects of anticoagulant therapy re‐initiation after gastrointestinal bleeding: A systematic review and meta‐analysis. Journal of Clinical Pharmacy and Therapeutics 46:6, pages 1509-1518.
Crossref
Crossref
Danielle H. RochlinClifford C. SheckterChristopher PannucciArash Momeni. (2020) Venous Thromboembolism following Microsurgical Breast Reconstruction: A Longitudinal Analysis of 12,778 Patients. Plastic & Reconstructive Surgery 146:3, pages 465-473.
Crossref
Crossref
Christopher Storey, Jonathon Lebovitz, Ahmad Sweid, Stavropoula Tjoumakaris, Reid Gooch, Robert H. Rosenwasser & Pascal Jabbour. (2019) Bilateral Mechanical Thrombectomies for Simultaneous MCA Occlusions. World Neurosurgery 132, pages 165-168.
Crossref
Crossref
Monami Ando, Yasuya Inden, Yukihiko Yoshida, Akinori Sairaku, Satoshi Yanagisawa, Hirohiko Suzuki, Ryo Watanabe, Masaki Takenaka, Mayuho Maeda & Toyoaki Murohara. (2019) Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart and Vessels 34:9, pages 1533-1541.
Crossref
Crossref
Nicolás E. Núñez-Navarro, Fabián M. Santana, Loreto P. Parra & Flavia C. Zacconi. (2019) Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa. Current Medicinal Chemistry 26:17, pages 3175-3200.
Crossref
Crossref
Marta Tena-Solsona, Domenico Marson, Ana C. Rodrigo, Stephen M. Bromfield, Beatriu Escuder, Juan F. Miravet, Nadezda Apostolova, Erik Laurini, Sabrina Pricl & David K. Smith. (2019) Self-assembled multivalent (SAMul) ligand systems with enhanced stability in the presence of human serum. Biomaterials Science 7:9, pages 3812-3820.
Crossref
Crossref
Flavia C. Zacconi. 2018. Anticoagulant Drugs. Anticoagulant Drugs.
David K. Smith. (2018) From fundamental supramolecular chemistry to self-assembled nanomaterials and medicines and back again – how Sam inspired SAMul. Chemical Communications 54:38, pages 4743-4760.
Crossref
Crossref
G. Göndör & C. Stöllberger. (2017) Pulmonary embolism four days after interruption of therapy with rivaroxaban. Hämostaseologie 37:4, pages 302-306.
Crossref
Crossref
Laura M. Haynes, Thomas Orfeo, Kenneth G. Mann, Stephen J. Everse & Kathleen E. Brummel-Ziedins. (2017) Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates. Biophysical Journal 112:8, pages 1634-1644.
Crossref
Crossref
Kaoru Okishige, Tomofumi Nakamura, Hideshi Aoyagi, Naohiko Kawaguchi, Mitsumi Yamashita, Manabu Kurabayashi, Hidetoshi Suzuki, Mitsutoshi Asano, Tsukasa Shimura, Yasuteru Yamauchi, Tetsuo Sasano & Kenzo Hirao. (2017) Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. Journal of Cardiology 69:1, pages 11-15.
Crossref
Crossref
S Elad, J Marshall, C Meyerowitz & G Connolly. (2016) Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Diseases 22:1, pages 23-32.
Crossref
Crossref
Li-Jun Chen, Yuan-Yuan Ren, Nai-Wei Wu, Bin Sun, Jian-Qiu Ma, Li Zhang, Hongwei Tan, Minghua Liu, Xiaopeng Li & Hai-Bo Yang. (2015) Hierarchical Self-Assembly of Discrete Organoplatinum(II) Metallacycles with Polysaccharide via Electrostatic Interactions and Their Application for Heparin Detection. Journal of the American Chemical Society 137:36, pages 11725-11735.
Crossref
Crossref
TOMOYUKI NAGAO, YASUYA INDEN, MASAYUKI SHIMANO, MASAYA FUJITA, SATOSHI YANAGISAWA, HIROYUKI KATO, SHINJI ISHIKAWA, AYA MIYOSHI, SATOSHI OKUMURA, SHIOU OHGUCHI, TOSHIHIKO YAMAMOTO, NAOKI YOSHIDA, MAKOTO HIRAI & TOYOAKI MUROHARA. (2015) Efficacy and Safety of Apixaban in the Patients Undergoing the Ablation of Atrial Fibrillation. Pacing and Clinical Electrophysiology 38:2, pages 155-163.
Crossref
Crossref
Vladimir B. Sulimov, Irina V. Gribkova, Maria P. Kochugaeva, Ekaterina V. Katkova, Alexey V. Sulimov, Danil C. Kutov, Khidmet S. Shikhaliev, Svetlana M. Medvedeva, Michael Yu. Krysin, Elena I. Sinauridze & Fazoil I. Ataullakhanov. (2015) Application of Molecular Modeling to Development of New Factor Xa Inhibitors. BioMed Research International 2015, pages 1-15.
Crossref
Crossref
B. Weiler, E. T. Marciniak, R. M. Reed & M. T. McCurdy. (2014) Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran. Case Reports 2014:jul04 1, pages bcr2014203910-bcr2014203910.
Crossref
Crossref
J. Kosiuk, E. Koutalas, M. Doering, P. Sommer, S. Rolf, O.-A. Breithardt, S. Nedios, B. Dinov, G. Hindricks, S. Richter & A. Bollmann. (2014) Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. Europace 16:7, pages 1028-1032.
Crossref
Crossref
Stephen M. Bromfield, Paola Posocco, Ching W. Chan, Marcelo Calderon, Scott E. Guimond, Jeremy E. Turnbull, Sabrina Pricl & David K. Smith. (2014) Nanoscale self-assembled multivalent (SAMul) heparin binders in highly competitive, biologically relevant, aqueous media. Chemical Science 5:4, pages 1484.
Crossref
Crossref
Akinori Sairaku, Yukihiko Yoshida, Monami Ando, Haruo Hirayama, Yukiko Nakano & Yasuki Kihara. (2013) A Head-to-Head Comparison of Periprocedural Coagulability Under Anticoagulation with Rivaroxaban Versus Dabigatran in Patients Undergoing Ablation of Atrial Fibrillation. Clinical Drug Investigation 33:11, pages 847-853.
Crossref
Crossref
Stephen M. Bromfield, Ellis Wilde & David K. Smith. (2013) Heparin sensing and binding – taking supramolecular chemistry towards clinical applications. Chemical Society Reviews 42:23, pages 9184.
Crossref
Crossref
Laura M. HaynesThomas OrfeoKenneth G. Mann. (2012) Rivaroxaban Delivery and Reversal at a Venous Flow Rate. Arteriosclerosis, Thrombosis, and Vascular Biology 32:12, pages 2877-2883.
Crossref
Crossref
Bengt I. Eriksson, John J. Smith, Joseph Caprini, Stefan Hantel, Andreas Clemens, Martin Feuring, Janet Schnee & Gregory W. Barsness. (2012) Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: Findings from four Phase 3 trials. Thrombosis Research 130:3, pages 396-402.
Crossref
Crossref
Rami A. Al-Horani, Akul Y. Mehta & Umesh R. Desai. (2012) Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold. European Journal of Medicinal Chemistry 54, pages 771-783.
Crossref
Crossref
Jawed FareedIndermohan Thethi & Debra Hoppensteadt. (2012) Old Versus New Oral Anticoagulants: Focus on Pharmacology. Annual Review of Pharmacology and Toxicology 52:1, pages 79-99.
Crossref
Crossref
Iván Mauricio Alvarado Arteaga. (2012) Current trends in the preoperative management of patients receiving warfarin for anticoagulation. Colombian Journal of Anesthesiology 40:1, pages 52-59.
Crossref
Crossref
Iv?n Mauricio Alvarado Arteaga. (2012) Tendencias actuales en el manejo preoperatorio de pacientes anticoagulados con warfarina. Revista Colombiana de Anestesiolog?a 40:1, pages 52-59.
Crossref
Crossref
Iván Mauricio Alvarado Arteaga. (2012) Current trends in the preoperative management of patients receiving warfarin for anticoagulation. Colombian Journal of Anesthesiology 40:1, pages 52-59.
Crossref
Crossref
Steven B. Deitelzweig, Jay Lin & Grace Lin. (2011) Preventing Venous Thromboembolism Following Orthopedic Surgery in the United States. Clinical and Applied Thrombosis/Hemostasis 17:6, pages 640-650.
Crossref
Crossref
Y. D. Kim, J. H. Lee, Y. H. Jung, M.-J. Cha, H. Y. Choi, C. M. Nam, J. H. Yang, H. J. Cho, H. S. Nam, K.-Y. Lee & J. H. Heo. (2011) Effect of warfarin withdrawal on thrombolytic treatment in patients with ischaemic stroke. European Journal of Neurology 18:9, pages 1165-1170.
Crossref
Crossref
Antonio G?mez-Outes, Maria Luisa Su?rez-Gea, Ram?n Lecumberri, Eduardo Rocha, Carmen Pozo-Hern?ndez & Emilio Vargas-Castrill?n. (2010) New parenteral anticoagulants in development. Therapeutic Advances in Cardiovascular Disease 5:1, pages 33-59.
Crossref
Crossref
Michael Huo. (2017) New oral anticoagulants in venous thromboembolism prophylaxis in orthopaedic patients: Are they really better?. Thrombosis and Haemostasis 106:07, pages 45-57.
Crossref
Crossref
Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza & Frank Misselwitz. (2010) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nature Reviews Drug Discovery 10:1, pages 61-75.
Crossref
Crossref
Renato D. Lopes, John H. Alexander, Sana M. Al-Khatib, Jack Ansell, Raphael Diaz, J. Donald Easton, Bernard J. Gersh, Christopher B. Granger, Michael Hanna, John Horowitz, Elaine M. Hylek, John J.V. McMurray, Freek W.A. Verheugt & Lars Wallentin. (2010) Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal 159:3, pages 331-339.
Crossref
Crossref
Alexander G. G. Turpie. 2009. New Therapeutic Agents in Thrombosis and Thrombolysis. New Therapeutic Agents in Thrombosis and Thrombolysis
307
326
.
Matthias Orth. (2009) Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der Prävention und Therapie von Thrombosen. LaboratoriumsMedizin 33:2, pages 121-127.
Crossref
Crossref
Sophie Alloul, Nagib Dahdah & Joaquim Miró. (2008) Thrombus in a Coronary Artery Aneurysm Shortly After Warfarin Withdrawal. Pediatric Cardiology 30:2, pages 188-190.
Crossref
Crossref
Michael R. Lassen, Walter Ageno, Lars C. Borris, Jay R. Lieberman, Nadia Rosencher, Tiemo J. Bandel, Frank Misselwitz & Alexander G.G. Turpie. (2008) Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty. New England Journal of Medicine 358:26, pages 2776-2786.
Crossref
Crossref
Eric A. MillicanPetra A. LenziniPaul E. MilliganLeonard GrossoCharles EbyElena DeychGloria GriceJohn C. Clohisy, Robert L. Barrack, R. Stephen J. Burnett, Deepak VooraSusan GatchelAmy TiemeierBrian F. Gage. (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110:5, pages 1511-1515.
Crossref
Crossref
A. G.G. Turpie. (2007) Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology 27:6, pages 1238-1247.
Crossref
Crossref
BRIGITTE E. ICKX & SERGE MOTTE. (2006) Perioperative management of oral anticoagulation. Transfusion Alternatives in Transfusion Medicine 8:3, pages 143-150.
Crossref
Crossref
. (2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:9.
Crossref
Crossref